Ixekizumab
Ixekizumab (pronunciation: /ɪksɛkɪzʊmæb/) is a type of biologic medication used in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is marketed under the brand name Taltz by Eli Lilly and Company.
Etymology
The name Ixekizumab is derived from the International Nonproprietary Names (INN) system, which is used to name pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the "xi-" prefix denotes that it is a chimeric human-mouse antibody. The "kiz-" stem is used for immunomodulating monoclonal antibodies.
Pharmacology
Ixekizumab works by targeting a specific protein in the body called interleukin 17A (IL-17A), which is involved in inflammatory and immune responses. By blocking the action of IL-17A, Ixekizumab can help to reduce the inflammation and other symptoms associated with conditions like psoriasis and psoriatic arthritis.
Related Terms
- Biologic
- Monoclonal antibody
- Psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Interleukin 17A
- Eli Lilly and Company
See Also
- List of monoclonal antibodies
- List of drugs used for psoriasis
- List of drugs used for psoriatic arthritis
- List of drugs used for ankylosing spondylitis
External links
- Medical encyclopedia article on Ixekizumab
- Wikipedia's article - Ixekizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski